Mon panier

Monoclonal Anti-Belantamab Antibody, Mouse IgG1 (8H4)

Avis des utilisateurs
Numéro de produit/spécification
Prix
Availability
Qté
BEB-MY2505-100ug
$355.00
In Stock - Delivery in 2-3 business days
BEB-MY2505-1mg (500ug X 2)
$2695.00
In Stock - Delivery in 2 weeks
Total des articles Montant du produit$ 0

Détails du produit

  • Source

    Chimeric Monoclonal Anti-Belantamab Antibody, Mouse IgG1 (8H4) is recombinantly expressed in HEK293. It consists of mouse variable regions genetically fused to mouse IgG1 constant domains.

  • Antibody Type

    Recombinant Monoclonal

  • Clone

    8H4

  • Isotype

    Mouse IgG1, Kappa

  • Host Species

    Mouse

  • Specificity

    Specifically recognizes Human Belantamab; This antibody is a neutralizing antibody.

  • Application

    Application
    Recommended Use / Performance
    ELISA
    0.2-2 μg/mL
  • Purification

    Protein A purified.

  • Aggregation

    Less than 5%, as determined by SEC-MALS.

  • Concentration

    Please refer to the Certificate of Analysis (CoA).

  • Form

    Lyophilized

  • Formulation

    Lyophilized from a 0.22 μm-filtered solution in PBS (pH 7.4), with trehalose as protectant.

    Please contact us for customized product forms or formulations.

  • Reconstitution

    Please refer to the Certificate of Analysis (CoA) for specific instructions.

  • Shipping

    Lyophilized product is shipped at ambient temperature.

  • Storage

    For long term storage, the product should be stored in a lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • Notices

    Product Specific Notices: For research use only.

  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • Bioactivity-ELISA

     Belantamab ELISA

    Immobilized Monoclonal Anti-Belantamab Antibody, Mouse IgG1 (8H4) (Cat. No. BEB-MY2505) at 5 μg/mL, add Belantamab and then add Biotinylated Monoclonal Anti-Belantamab Antibody, Mouse IgG1 (13D8) (Cat. No. BEB-BMY2503) at 1 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) (QC tested).

    Protocol

Avis des utilisateurs
Publier un commentaire

FAQ

  • product

    Can lyophilized proteins remain stable during room-temperature shipping or temporary room-temperature exposure?

    In general, lyophilized proteins remain stable during room-temperature shipping or temporary exposure to room-temperature conditions.


    Many ACROBiosystems recombinant proteins are supplied in lyophilized (freeze-dried) form. The lyophilization process effectively removes moisture from the product, helping reduce degradation-related reactions and improve protein stability during transportation and storage.


    To evaluate the stability of lyophilized proteins under normal temperature conditions, ACROBiosystems conducted a stability study on 11 representative lyophilized protein products at 37°C. The study demonstrated that these proteins maintained good quality stability after storage at 37°C for approximately 20 days. Based on these validation results, temporary room-temperature exposure during shipping or handling is generally not expected to have a significant impact on product quality or downstream application performance.


    To ensure optimal long-term stability, products should be stored according to the storage conditions specified in the product Certificate of Analysis (COA) upon receipt.


    Supporting Document


Introduction de fond

Belantamab is a B-cell maturation antigen (BCMA) binding humanized monoclonal antibody. Belantamab is composed of the Fv (variable; antigen-binding) regions of the CA8 murine BCMA monoclonal antibody specific for the extracellular domain of human BCMA with human IgG1 heavy and kappa light chain constant (framework) regions.

Progrès de frontière

 
Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs
  • FAQ
  • Contexte